Skip to main content
This section has no specific content
You will be redirected to the website of ROVI Spain in 5 seconds, where we will expand the information requested.
ACCESS
NO ACCESS
This section has no specific content
You will be redirected to the website of ROVI Spain in 5 seconds, where we will expand the information requested.
ACCESS
NO ACCESS
This section has no specific content
You will be redirected to the website of ROVI Spain in 5 seconds, where we will expand the information requested.
ACCESS
NO ACCESS
ROVI Subsidiaries
Spain
France
Italy
Germany
Poland
Portugal
United Kingdom
Ethics channel
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Enoxaparin Biosimilar
Contact
Products
Hospital Products
Diagnostic Products
OTC Products
Manufacturing
Contract manufacturing
Own product Manufacturing
R&D
Pipeline
ISM
Glycomics
Multilayer technologies
Shareholders and Investors
General information on the Company
How to contact the Company
Shares and share capital
Investor Agenda
Dividends
Public offerings and admission to trading
Public tender offers
Bylaws
Relevant events
Shareholders agreements
Significant interests and treasury shares
Analyst Coverage
Financial and economic information
Audit Report, Audited Annual Financial Statements (individual and consolidated), Management Report and Annual Report
Regular Public Information
Public information sent to regulatory bodies, other than information prepared under Spanish regulations
Rating
Average payment period to suppliers
Share Evolution
Stock Market History
Economic information
Share Value
Corporate Governance
Regulations of the Shareholders Meeting
General Shareholders' Meeting: exercising the right to information
Notice and Agenda of the Meeting
Shareholders request for information or clarification
Proxy voting
Distance voting at General Meetings
Information on the contents of past General Meetings
Board of Directors
Regulations of the Board of Directors
Annual Corporate Governance Report
Director compensation
Board Committees
Corporate Policies
Full texts of the proposed resolutions to be taken and the documentation available to the shareholder prior to the Meeting
Internal rules of conduct relating to trading in the securities market
Contact
Information for Investors
Annual Reports
Press Releases
Information for investors
Webcasts and other presentations
Contact
CSR
Mission, vision and values
Relations with Stakeholders
Commitment to Society
Commitment to the environment
Commitment to the employees
Media
FAQS
News
Contact
Work with Us
INTRANET
Home
Contact
News
News
Find out more …
FAQs
News
Contact
Filtrar resultados
Año
Year
-Year
2021
2022
2023
2024
2025
2026
2027
Desde
Date
E.g., 11/24/2024
Hasta
Date
E.g., 11/24/2024
26/04/2012
2012 First Quarter Results
126i.pdf
26/04/2012
2012 First Quarter Results Presentation
127i.pdf
21/02/2012
2011 full year results press release
124i.pdf
21/02/2012
2011 full year results presentation
125i.pdf
15/02/2012
Corlentor® receives approval for use in heart failure
123i.pdf
08/11/2011
9M 2011 Interim Statement
121i.pdf
08/11/2011
Nine-month period ended 30 September 2011 Results Presentation
122i.pdf
19/10/2011
Results of the final analysis of the ABEL Phase II clinical trial
120i.pdf
26/09/2011
Alentia Biotech plans to construct a national production centre to supply the Spanish population with flu vaccines
119i.pdf
01/09/2011
New results from the SHIFT study in heart failure patients with Corlentor
118i.pdf
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »